The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) submitted a notice on January 14, 2025, to the Attorney General and the Federal Trade Commission regarding changes in its membership. This action aims to ensure the Consortium's activities remain protected under the National Cooperative Research and Production Act, which limits antitrust plaintiffs' recovery to actual damages in certain cases. Several companies, including Bella Biologics and CellCo, were added as parties to the venture. The group maintains an open membership and plans further notifications for any additional changes.
Simple Explanation
The Biopharmaceutical Manufacturing Preparedness Consortium told the government about new companies joining their group so they can work together better on making medicine. This helps them stay protected under special rules that make it harder for others to sue them for a lot of money.